Infect Chemother.  2012 Jun;44(3):164-167. 10.3947/ic.2012.44.3.164.

National Campaign for Appropriate Antibiotic Use in Korea

• Chung DR
• Song JH
• The Korean Society of Infectious Diseases

• KMID: 2170365
• DOI: http://doi.org/10.3947/ic.2012.44.3.164

Abstract

The growing problem of antimicrobial resistance imposes limitations on successful treatment of infection and also has a significant socioeconomic impact. Emergence of multidrug-resistant organisms and their rapid intercontinental spread, as well as a lack of new antibiotics in the developmental pipeline, have led all stakeholders to take action. Despite reduced consumption of antimicrobials and improvement in appropriate use of antibiotics during the past decade in Korea, such efforts should be further enhanced and an increase in public awareness is needed. A public campaign for 'appropriate antibiotic use' was launched in Korea in November 2011. This campaign, organized by the Korean Society of Infectious Diseases and the Korean Society for Chemotherapy, and sponsored by the Korea CDC, the Korean Society of Pediatric Infectious Diseases, and the Asia Pacific Foundation for Infectious Diseases, has targeted both members of the general public and healthcare professionals. Contents include development and distribution of posters, leaflets, and e-learning programs, education of school nurses, leading to indirect education of students, and mass media campaigns. We hope that this campaign will contribute to an increase in public awareness and that it will encourage both members of the general public and healthcare professionals to join in the effort to overcome a crisis of antimicrobial resistance.

Keyword

Microbial drug resistance; Anti-infective agents; Drug utilization review; Awareness; Campaign

MeSH Terms

Anti-Bacterial Agents
Anti-Infective Agents
Asia
Centers for Disease Control and Prevention (U.S.)
Communicable Diseases
Delivery of Health Care
Drug Utilization Review
Humans
Korea
Mass Media
Anti-Bacterial Agents
Anti-Infective Agents

Reference

1. Kim SH, Song JH, Chung DR, Thamlikitkul V, Yang Y, Wang H, Lu M, So TM, Hsueh PR, Yasin RM, Carlos CC, Pham HV, Lalitha MK, Shimono N, Perera J, Shibl AM, Baek JY, Kang CI, Ko KS, Peck KR. ANSORP Study Group. Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study. Antimicrob Agents Chemother. 2012. 56:1418–1426.

2. Song JH, Hsueh PR, Chung DR, Ko KS, Kang CI, Peck KR, Yeom JS, Kim SW, Chang HH, Kim YS, Jung SI, Son JS, So TM, Lalitha MK, Yang Y, Huang SG, Wang H, Lu Q, Carlos CC, Perera JA, Chiu CH, Liu JW, Chongthaleong A, Thamlikitkul V, Van PH. ANSORP Study Group. Spread of methicillin-resistant Staphylococcus aureus between the community and the hospitals in Asian countries: an ANSORP study. J Antimicrob Chemother. 2011. 66:1061–1069.

3. Lee K, Kim MN, Kim JS, Hong HL, Kang JO, Shin JH, Park YJ, Yong D, Jeong SH, Chong Y. KONSAR Group. Further increases in carbapenem-, amikacin-, and fluoroquinolone-resistant isolates of Acinetobacter spp. and P. aeruginosa in Korea: KONSAR study 2009. Yonsei Med J. 2011. 52:793–802.

4. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, Chaudhary U, Doumith M, Giske CG, Irfan S, Krishnan P, Kumar AV, Maharjan S, Mushtaq S, Noorie T, Paterson DL, Pearson A, Perry C, Pike R, Rao B, Ray U, Sarma JB, Sharma M, Sheridan E, Thirunarayan MA, Turton J, Upadhyay S, Warner M, Welfare W, Livermore DM, Woodford N. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010. 10:597–602.

5. Owens RC Jr. Antimicrobial stewardship: concepts and strategies in the 21st century. Diagn Microbiol Infect Dis. 2008. 61:110–128.

6. Roberts RR, Hota B, Ahmad I, Scott RD 2nd, Foster SD, Abbasi F, Schabowski S, Kampe LM, Ciavarella GG, Supino M, Naples J, Cordell R, Levy SB, Weinstein RA. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis. 2009. 49:1175–1184.

7. Klevens RM, Edwards JR, Richards CL Jr, Horan TC, Gaynes RP, Pollock DA, Cardo DM. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep. 2007. 122:160–166.

8. Maragakis LL, Perencevich EN, Cosgrove SE. Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther. 2008. 6:751–763.

9. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009. 48:1–12.

10. Aiello AE, King NB, Foxman B. Ethical conflicts in public health research and practice: antimicrobial resistance and the ethics of drug development. Am J Public Health. 2006. 96:1910–1914.

11. Goossens H, Ferech M, Vander Stichele R, Elseviers M. ESAC Project Group. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005. 365:579–587.

12. Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med. 1999. 341:233–239.

13. Park S, Moon OR. Patterns of antibiotics utilization in some respiratory diseases in clinics. Journal of Korean Society of Quality Assurance in Health Care. 1998. 5:58–75.

14. Wise R, Hart T, Cars O, Streulens M, Helmuth R, Huovinen P, Sprenger M. Antimicrobial resistance. Is a major threat to public health. BMJ. 1998. 317:609–610.

15. Seppälä H, Klaukka T, Vuopio-Varkila J, Muotiala A, Helenius H, Lager K, Huovinen P. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med. 1997. 337:441–446.

16. Austin DJ, Kristinsson KG, Anderson RM. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc Natl Acad Sci U S A. 1999. 96:1152–1156.

17. Gottesman BS, Carmeli Y, Shitrit P, Chowers M. Impact of quinolone restriction on resistance patterns of Escherichia coli isolated from urine by culture in a community setting. Clin Infect Dis. 2009. 49:869–875.

18. Park S, Soumerai SB, Adams AS, Finkelstein JA, Jang S, Ross-Degnan D. Antibiotic use following a Korean national policy to prohibit medication dispensing by physicians. Health Policy Plan. 2005. 20:302–309.

19. Kim SK, Kim HE, Back MS, Lee SH. The effect of public report on antibiotics prescribing rate. Kor J Clin Pharm. 2010. 20:242–247.

20. Kim ES, Park SW, Lee CS, Gyung Kwak Y, Moon C, Kim BN. Impact of a national hospital evaluation program using clinical performance indicators on the use of surgical antibiotic prophylaxis in Korea. Int J Infect Dis. 2012. 16:e187–e192.

21. Song JH. Evaluation of consumer perception and knowledge on antimicrobial resistance in Korea. The report of Korea Food & Drug Administration. 2010.

22. Organization WH. Overcoming antimicrobial resistance. World Health Organization Report on Infectious Diseases. 2000.

23. Anonymous. Antimicrobial resistance: revisiting the "tragedy of the commons". Bull World Health Organ. 2010. 88:805–806.

24. Get smart: know when antibiotics work. Centers for Disease Control and Prevention. Accessed 19 June 2012. Available at: http://www.cdc.gov/getsmart.

25. European antibiotic awareness day is marked annually on 18 November. European Antibiotic Awareness Day. Accessed 19 June 2012. Available at: http://ecdc.europa.eu/en/eaad.

26. National campaign for appropriate antibiotic use in Korea. The Korean Society of Infectious Diseases, Korean Society for Chemotherapy. Accessed 19 June 2012. Available at: http://www.antibioticuse.org.